BioAro, a leader in genomic research and technology, has recently introduced PanOmiQ, an innovative software that is set to transform the landscape of global genomic analysis by providing real-time insights into the complexities of the human genome. With unparalleled speed, precision, and adaptability, it is poised to revolutionize healthcare on a global scale.

The global launch of PanOmiQ software took place at the Precision Medicine Expo on May 9 at Dubai World Trade Centre. The event was attended by representatives of the Consulate General of Canada, Dr Raees Tonse, Advisor to the Royal Family Office and project lead of Longevi-City in Ras Al Khaimah, George P Patrinos, professor, division head and head of laboratory, editor-in-chief of the Pharmacogenomics Journal, Harish Consul, founder and CEO, Ocgrow Ventures, and Divya Mishra, Bioinformatician, BioAro.

Genomic analysis involves the identification, measurement or comparison of genomic features such as DNA sequence, structural variation, gene expression, or regulatory and functional element annotation at a genomic scale. BioAro’s revolutionary software PanOmiQ is tailored to simplify this challenging process.

PanOmiQ is a cutting-edge software platform designed for comprehensive 'Omics' analysis and reporting. It offers an all-in-one solution for genetic analysis and report generation, revolutionizing the world of genetic analysis by enabling comprehensive analysis of diverse omic data types within a single, seamless interface.

Dr Anmol S Kapoor, founder and CEO at BioAro, stated, “PanOmiQ is the world's fastest genomic analysis software to date. With its unified approach to integrating primary, secondary, and tertiary analysis of genomic and metagenomic data, it empowers healthcare specialists to decode DNA sequences in real-time, facilitating informed decision-making.”

Dr Raja B Singh, chief scientific officer at BioAro, emphasized, “Turnaround time in genomic analysis is crucial, and this is where PanOmiQ excels with its unmatched speed, accuracy, and proprietary AI-based platform providing clinical annotations and enhancing disease risk understanding.”

PanOmiQ, powered by artificial intelligence, accelerates the identification of rare diseases, health predispositions, and pharmacogenomic insights with exceptional speed and precision. Its ability to provide Pharmacogenomic analysis represents a significant advancement in tailoring treatment for optimized patient care.

Dr Raees Tonse highlighted, “PanOmiQ is a game-changer in precision healthcare, not only for this region, but for the whole mankind. It will revolutionize the future of human health, contributing to increased life-spans and reinforcing UAE’s position as a future hub of precision healthcare and medicine.”

BioAro's PanOmiQ is at the forefront of the transformation of genomic science with the integration of Quantum technology. Through harnessing Quantum technology, it redefines possibilities in this field, advancing the future of genomic research with real-time, precise genomic sequencing and interpretation on quantum-based computers.